1-Bromo-2-Butyne CAS 3355-28-0 Puritas ≥99.0% (GC) Linagliptin Intermedia Factory
Manufacturer Supple Linagliptin et intermedia:
Linagliptin CAS 668270-12-0
Linagliptin Parent Nucleus Intermedia CAS 853029-57-9
8-Bromo-3-Methylxanthine CAS 93703-24-3
8-Bromo-7-(2-butyn-1-yl) -3-methylxanthine CAS 666816-98-4
2-(Chloromethyl) -4-Methylquinazoline CAS 109113-72-6
(R) -3-(Boc-Amino) piperidine CAS 309956-78-3
(R)-(-)-3-Aminopiperidine dihydrochloride CAS 334618-23-4
1-Bromo-2-Butyne CAS 3355-28-0
Nomen chemicum | 1-Bromo-2-Butyne |
Synonyma | 2-Butynyl Bromide |
CAS Number | 3355-28-0 |
CATTUS Number | RF-PI500 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C4H5Br |
M. Pondus | 132.99 |
Ferveret | 40.0~41.0/20 mmHg (lit.) |
Density | 1.519 g/ml ad 25℃ (lit.) |
Index refractivus | n20/D 1.508(lit.) |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Hyalina levi Yellow Liquid |
Puritas / Analysis Methodus | ≥99.0% (GC) |
Humor (KF) | ≤0.20% |
Residere in Ignition | ≤0.10% |
una immunditia | ≤0.30% |
Totalis immunditias | ≤1.0% |
Dicta | Color erit obscurior postquam expositae aeri frequenter |
Copia in caliginoso, caliginoso, sicco et nitrogenito loco munito | |
Utere eum quam primum post foramen | |
Test Standard | Enterprise Standard |
Consuetudinem | Pharmaceutical intermedia |
sarcina: Utrem, 25kg/ Ferocactus vel 220kg Plastic tympanum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.
1-Bromo-2-Butyne (CAS: 3355-28-0) late in synthesi organica, synthesis intermediorum pharmaceuticorum et synthesis pharmaceuticae activae.1-Bromo-2-Butyne clavis media est in synthesi Linagliptin (CAS: 668270-12-0) ad adultorum genus diabetes melliti curandos.1-Bromo-2-Butyne est chemicus, qui in synthesi compositionum chiralium teranyl axially abutitur, alkylation L-tryptophan methyl ester, 4-butynyloxybenzene sulfonyl chloride et mono-propargylata diene derivativa.Praeter haec, etiam in synthesi isopropylbut-2-ynylamine, derivatis allenylcyclobutanolis, allyl-[4-(sed-2-ynyloxy)phenyl]sulfane, allenylindium et axialiter chiralum teranyl compositum.